Newswise – FORT WASHINGTON, PA – According to the NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia , the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy. [1] “Acute Lymphoblastic Leukemia is a very aggressive disease and patients are faced with a multitude of decisions in a short period of time,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation.
